8-KOther EventsExhibits & Filings

CVS HEALTH Corp 8-K Report, Corporate Update (Feb 13, 2007)

Filed February 13, 2007For Securities:CVS

Summary

CVS Health Corporation (CVS) filed an 8-K on February 13, 2007, primarily to update its joint proxy statement/prospectus regarding the pending merger with Caremark Rx, Inc. The key development reported is an amendment to a Waiver Agreement, which significantly increases the special cash dividend payable to Caremark stockholders from $2.00 per share to $6.00 per share. This amendment, executed on February 12, 2007, required the approval of the CVS Board of Directors, who consulted with their financial advisors, Evercore Group L.L.C. and Lehman Brothers Inc. Both financial advisors provided opinions to the CVS Board on February 12, 2007, confirming that the exchange ratio in the merger was fair, from a financial point of view, to CVS. These opinions were based on extensive financial analyses, including peer group trading, precedent transactions, and discounted cash flow analyses. The 8-K also incorporates revised unaudited pro forma condensed combined financial information reflecting these changes. The increased dividend and the fairness opinions are critical pieces of information for investors evaluating the merger's terms and potential impact.

Key Highlights

  • 1CVS Health Corp. (CVS) amended its Merger Agreement with Caremark Rx, Inc. (Caremark) by increasing the special cash dividend for Caremark stockholders from $2.00 to $6.00 per share.
  • 2The amendment to the Waiver Agreement was executed on February 12, 2007, and the Caremark Board of Directors declared the $6.00 special dividend, contingent upon the merger's completion.
  • 3The CVS Board of Directors, after consultation with financial advisors, approved the increase in the special cash dividend.
  • 4Both Evercore Group L.L.C. and Lehman Brothers Inc., financial advisors to the CVS Board, delivered fairness opinions on February 12, 2007, stating the merger's exchange ratio was financially fair to CVS.
  • 5The 8-K filing includes updated unaudited pro forma condensed combined financial information reflecting the merger and the increased dividend.
  • 6The accelerated share repurchase transaction planned post-merger remains unaffected by the waiver amendment.
  • 7The filing serves to update previously filed documents, specifically the joint proxy statement/prospectus filed on Form S-4.

Frequently Asked Questions